ReviewDiscover oncology2025

Should CDK4/6 inhibitors replace chemotherapy in HR+ /HER2- metastatic breast cancer with visceral crisis? Evaluating the emerging evidence.

Armando OrlandiPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.